MYC-related drug effect enrichments arsenic trioxide azacitidine cisplatin dactinomycin Renal and urinary disorders Vascular Bladder disorders Bladder Reproductive disorders and system NEC Hepatobiliary bladder and disorders breast neck disorders disorders (excl calculi) decitabine deferoxamine doxorubicin dronabinol Neoplasms benign, Lower 95% Lower Bound Confidence Interval malignant respiratory and tract Skin and unspecified disorders Investigations subcutaneous (incl (excl tissue obstruction cysts disorders and and infection) polyps) etoposide fluorouracil teniposide mitoxantrone Injury, poisoning Injury, Arteriosclerosis, and poisoning stenosis, Seizures procedural and vascular (incl Administration complications procedural insufficiency subtypes) site complications and reactions necrosis Congenital, Application Nervous Reproductive Vascular Vascular familial system system disorders disorders instillation disorders and and site genetic breast reactions disorders disorders early adolescence tal interior toddler inthood late adolescence term neonatal interior toddler inthood introod early and late adolescence term neonatal interior toddler inthood introod early adolescence tretinoin vorinostat Application and instillation Investigations site Epidermal reactions and dermal conditions Skin and Administration subcutaneous site tissue reactions disorders middle childhood eally adolescence -Te adolescence eath adolescence vate adolescence middle childhood early childhood early childhood toddlei

myc_expression

downregulated MYC expression

upregulated MYC expression